Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download ChromeDownload Microsoft Edge
Press release

Board Appointment

June 18, 2021

Dr Ian Hudson to join as Independent Non-Executive Director

Oxford, U.K. 18 June 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the Clinical AI company, today announces the appointment of Dr Ian Hudson to the Board as Independent Non-Executive Director with effect from 28 June 2021. 

Dr Hudson has extensive knowledge of the healthcare and pharmaceutical sector, having served as Chief Executive of the UK’s Medicines and Healthcare Products Regulatory Agency (“MHRA”) between 2013 and 2019. Prior to this, he was the MHRA’s Licensing Director, responsible for most of the agency’s medicines licensing activities.

Before joining the MHRA, Dr Hudson held various senior roles at SmithKline Beecham, working for more than a decade in clinical research and development. Dr Hudson is currently serving as Senior Advisor, Integrated Development for the Bill and Melinda Gates Foundation, working in areas that include optimizing clinical studies and strengthening regulatory systems in low-resource regions, as well as providing regulatory input to teams working on malaria, polio, and COVID-19 drugs.

In 2020, he was awarded an OBE for Services to Healthcare, received a Faculty of Pharmaceutical Medicine President’s medal for contribution to pharmaceutical medicine, and was named a Global Fellow in Medicines Development by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine. 

Professor Sir Bruce Keogh, Non-Executive Chairman of Sensyne, said:

I am thrilled to welcome Ian to the Board at such an important time for Sensyne. Ian’s experience will be a great asset as we build an innovative and world class clinical artificial intelligence company.”

Dr Ian Hudson, Independent Non-Executive Director of Sensyne said:

“The COVID-19 pandemic has demonstrated how important clinical AI is to the effective management of health. Sensyne has been at the forefront of this trend, applying ethical AI to improving healthcare and life sciences research and I’m looking forward to supporting the company on what is an increasingly global journey.”

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Dr Ian Robert Burton Hudson (age 62) 

There is no further information required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules in respect of Dr Hudson.

Press release

Board Appointment

June 18, 2021

Dr Ian Hudson to join as Independent Non-Executive Director

Oxford, U.K. 18 June 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the Clinical AI company, today announces the appointment of Dr Ian Hudson to the Board as Independent Non-Executive Director with effect from 28 June 2021. 

Dr Hudson has extensive knowledge of the healthcare and pharmaceutical sector, having served as Chief Executive of the UK’s Medicines and Healthcare Products Regulatory Agency (“MHRA”) between 2013 and 2019. Prior to this, he was the MHRA’s Licensing Director, responsible for most of the agency’s medicines licensing activities.

Before joining the MHRA, Dr Hudson held various senior roles at SmithKline Beecham, working for more than a decade in clinical research and development. Dr Hudson is currently serving as Senior Advisor, Integrated Development for the Bill and Melinda Gates Foundation, working in areas that include optimizing clinical studies and strengthening regulatory systems in low-resource regions, as well as providing regulatory input to teams working on malaria, polio, and COVID-19 drugs.

In 2020, he was awarded an OBE for Services to Healthcare, received a Faculty of Pharmaceutical Medicine President’s medal for contribution to pharmaceutical medicine, and was named a Global Fellow in Medicines Development by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine. 

Professor Sir Bruce Keogh, Non-Executive Chairman of Sensyne, said:

I am thrilled to welcome Ian to the Board at such an important time for Sensyne. Ian’s experience will be a great asset as we build an innovative and world class clinical artificial intelligence company.”

Dr Ian Hudson, Independent Non-Executive Director of Sensyne said:

“The COVID-19 pandemic has demonstrated how important clinical AI is to the effective management of health. Sensyne has been at the forefront of this trend, applying ethical AI to improving healthcare and life sciences research and I’m looking forward to supporting the company on what is an increasingly global journey.”

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Dr Ian Robert Burton Hudson (age 62) 

There is no further information required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules in respect of Dr Hudson.

Press release

Board Appointment

Board Appointment

June 18, 2021

Dr Ian Hudson to join as Independent Non-Executive Director

Oxford, U.K. 18 June 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the Clinical AI company, today announces the appointment of Dr Ian Hudson to the Board as Independent Non-Executive Director with effect from 28 June 2021. 

Dr Hudson has extensive knowledge of the healthcare and pharmaceutical sector, having served as Chief Executive of the UK’s Medicines and Healthcare Products Regulatory Agency (“MHRA”) between 2013 and 2019. Prior to this, he was the MHRA’s Licensing Director, responsible for most of the agency’s medicines licensing activities.

Before joining the MHRA, Dr Hudson held various senior roles at SmithKline Beecham, working for more than a decade in clinical research and development. Dr Hudson is currently serving as Senior Advisor, Integrated Development for the Bill and Melinda Gates Foundation, working in areas that include optimizing clinical studies and strengthening regulatory systems in low-resource regions, as well as providing regulatory input to teams working on malaria, polio, and COVID-19 drugs.

In 2020, he was awarded an OBE for Services to Healthcare, received a Faculty of Pharmaceutical Medicine President’s medal for contribution to pharmaceutical medicine, and was named a Global Fellow in Medicines Development by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine. 

Professor Sir Bruce Keogh, Non-Executive Chairman of Sensyne, said:

I am thrilled to welcome Ian to the Board at such an important time for Sensyne. Ian’s experience will be a great asset as we build an innovative and world class clinical artificial intelligence company.”

Dr Ian Hudson, Independent Non-Executive Director of Sensyne said:

“The COVID-19 pandemic has demonstrated how important clinical AI is to the effective management of health. Sensyne has been at the forefront of this trend, applying ethical AI to improving healthcare and life sciences research and I’m looking forward to supporting the company on what is an increasingly global journey.”

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Dr Ian Robert Burton Hudson (age 62) 

There is no further information required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules in respect of Dr Hudson.

Press release

Board Appointment

Board Appointment

Dr Ian Hudson to join as Independent Non-Executive Director

Oxford, U.K. 18 June 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the Clinical AI company, today announces the appointment of Dr Ian Hudson to the Board as Independent Non-Executive Director with effect from 28 June 2021. 

Dr Hudson has extensive knowledge of the healthcare and pharmaceutical sector, having served as Chief Executive of the UK’s Medicines and Healthcare Products Regulatory Agency (“MHRA”) between 2013 and 2019. Prior to this, he was the MHRA’s Licensing Director, responsible for most of the agency’s medicines licensing activities.

Before joining the MHRA, Dr Hudson held various senior roles at SmithKline Beecham, working for more than a decade in clinical research and development. Dr Hudson is currently serving as Senior Advisor, Integrated Development for the Bill and Melinda Gates Foundation, working in areas that include optimizing clinical studies and strengthening regulatory systems in low-resource regions, as well as providing regulatory input to teams working on malaria, polio, and COVID-19 drugs.

In 2020, he was awarded an OBE for Services to Healthcare, received a Faculty of Pharmaceutical Medicine President’s medal for contribution to pharmaceutical medicine, and was named a Global Fellow in Medicines Development by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine. 

Professor Sir Bruce Keogh, Non-Executive Chairman of Sensyne, said:

I am thrilled to welcome Ian to the Board at such an important time for Sensyne. Ian’s experience will be a great asset as we build an innovative and world class clinical artificial intelligence company.”

Dr Ian Hudson, Independent Non-Executive Director of Sensyne said:

“The COVID-19 pandemic has demonstrated how important clinical AI is to the effective management of health. Sensyne has been at the forefront of this trend, applying ethical AI to improving healthcare and life sciences research and I’m looking forward to supporting the company on what is an increasingly global journey.”

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Dr Ian Robert Burton Hudson (age 62) 

There is no further information required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules in respect of Dr Hudson.

Arrange to meet us
Press release

Board Appointment

June 18, 2021

Dr Ian Hudson to join as Independent Non-Executive Director

Oxford, U.K. 18 June 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the Clinical AI company, today announces the appointment of Dr Ian Hudson to the Board as Independent Non-Executive Director with effect from 28 June 2021. 

Dr Hudson has extensive knowledge of the healthcare and pharmaceutical sector, having served as Chief Executive of the UK’s Medicines and Healthcare Products Regulatory Agency (“MHRA”) between 2013 and 2019. Prior to this, he was the MHRA’s Licensing Director, responsible for most of the agency’s medicines licensing activities.

Before joining the MHRA, Dr Hudson held various senior roles at SmithKline Beecham, working for more than a decade in clinical research and development. Dr Hudson is currently serving as Senior Advisor, Integrated Development for the Bill and Melinda Gates Foundation, working in areas that include optimizing clinical studies and strengthening regulatory systems in low-resource regions, as well as providing regulatory input to teams working on malaria, polio, and COVID-19 drugs.

In 2020, he was awarded an OBE for Services to Healthcare, received a Faculty of Pharmaceutical Medicine President’s medal for contribution to pharmaceutical medicine, and was named a Global Fellow in Medicines Development by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine. 

Professor Sir Bruce Keogh, Non-Executive Chairman of Sensyne, said:

I am thrilled to welcome Ian to the Board at such an important time for Sensyne. Ian’s experience will be a great asset as we build an innovative and world class clinical artificial intelligence company.”

Dr Ian Hudson, Independent Non-Executive Director of Sensyne said:

“The COVID-19 pandemic has demonstrated how important clinical AI is to the effective management of health. Sensyne has been at the forefront of this trend, applying ethical AI to improving healthcare and life sciences research and I’m looking forward to supporting the company on what is an increasingly global journey.”

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Dr Ian Robert Burton Hudson (age 62) 

There is no further information required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules in respect of Dr Hudson.